According to a research official, a major Israeli trial indicates that someone can still catch Omicron variant of the coronavirus even after four COVID-19 vaccine shots

By Victor Omondi

The study stated that although the extra dose of either Pfizer or Moderna vaccine appeared to have some promising effect, infection rates in the trial were not significantly different for those who received three Pfizer doses.

The study’s principal investigator Gili Regev-Yochay told reporters that “the vaccine is excellent against the Alpha and Delta,” but that “for Omicron, it’s not good enough,” The Times of Israel reported Monday evening.

The trial’s results weren’t released because the investigator said they were preliminary. However, she disclosed the preliminary findings because the public was interested.

If validated and vetted by other scientists after publication, the findings could strengthen arguments for the creation of a new COVID-19 vaccine. Vaccines for new sorts of diseases are already being developed.

Reuters reported that the Israeli trial, which began a month ago at the Sheba Medical Center, is looking into the effects of the Pfizer and Moderna boosters on 154 people and 120 people, respectively.

It discovered that individuals who received the fourth dose had an “increase in antibodies.”

Regev-Yochay, on the other hand, stated: “we see many infected with Omicron who received the fourth dose. Granted, a bit less than in the control group, but still a lot of infections.”

The people in the control group received three doses of the Pfizer vaccine.

Three doses of the Pfizer vaccine were administered to the control group.

According to the Times of Israel, approximately 500,000 fourth vaccination doses have been given in Israel as of Sunday.

Vaccines are still effective in preventing serious illness and hospitalization.

Data released on December 31 by the UK health security agency revealed that two doses of vaccine lowered the chance of hospitalization by 72% within 24 weeks following the second shot.

Over time, that protection decreased, but a third shot restored it, lowering the chance of hospitalization by 88% for at least two weeks.

Scientists thought that increased antibody levels following a booster dose, which were also detected after the third treatment, meant the body would be able to protect itself from infection and transmission from Omicron.

However, laboratory tests have revealed that the Omicron variant is extremely adept at evading antibodies that had previously been able to prevent previous coronavirus strains.

Israel, which has already given a third dose of vaccination to more than 45% of its population as of late December, has observed an increase in Omicron-related infections, albeit deaths have remained low.

Leave a Reply

%d bloggers like this: